Venus Concept (NASDAQ:VERO) Investor Overview

Winter 2024



Disclaimer

Non-Reliance

This presentation does not provide full disclosure of all material facts relating to Venus Concept Inc.(the "Company", "us" or "we"), or its securities, and is not subject to liability for misrepresentations under applicable securities legislation.

Cautionary Note Regarding Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "should," "could," "estimates," "predicts," "potential," "continue," "guidance," and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements include, but are not limited to, statements about our product and service offerings; financial performance and metrics; business growth prospects and aspirations; and the efficacy of the restructuring plan, workforce reduction and management transition. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which the Company operates and management's beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, general economic conditions and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements and those risks and uncertainties described under Part II Item IA—"Risk Factors" in our Quarterly Reports on Form 10-Q and Part I Item IA—"Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. You are urged to consider these factors carefully in evaluating the forward-looking statements.

All forward-looking statements in this presentation are based on information available to us as of the date of this presentation. Except as expressly required by applicable law, we assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

All of the forward-looking statements contained in this presentation are expressly qualified by the foregoing cautionary statement.

Securities Laws

This presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company nor shall there be any sale of Company securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Neither the United States Securities and Exchange Commission or any state securities commission or regulatory authority have passed on the accuracy or adequacy of this presentation. Any representation to the contrary is a criminal offense.



Investment Highlights

Venus Aesthetic Intelligence (Venus.AI) is a future-oriented approach to aesthetics innovation that aims to be transformational in delivering more than just leading device performance—with a shift towards total practice performance—from the moment the patient enters the clinic to post-treatment recovery

- Comprehensive aesthetic portfolio of innovative energy-based devices with market leading platforms in all key treatment segments, including Face/Skin, Body Contouring and Hair Removal
- Unique competitive positioning providing complete practice solutions for both Core (Physician) and fast-growing Non-Core (Medi-Spa) markets
- Market leading Robotic Hair Restoration business expanding core access to male aesthetics segment and offering tremendous option value for the Company
- Exciting and innovative Venus.AI technology pipeline, leveraging advanced R&D capabilities in energy-based technologies, robotics automation and AI/ML technologies, to deliver next-generation aesthetic robotics solutions (AI.ME)
- Scalable global operating infrastructure with established direct US/NA coverage and an expanding hybrid (direct/distributor) network delivering profitable international growth
- Successful business restructuring completed and capital restructuring near completion delivering right-sized cost base, enhanced quality of revenues and working capital efficiency, and a refocused innovation roadmap collectively providing a clear path to cash flow profitability and double-digit long-term growth



Company History & Leadership Team

Return to growth and clear path to cash flow break even long-term & Leadership change with NeoGraft 2011 2019 2023 financial sustainability Acquisition turnaround mandate 2024+ 2018 2022 Year of Foundation **Reverse Takeover** Achieved 50%+ of Restoration reduction in cash burn with refocused **Robotics** operations and new product launch plan



Rajiv De Silva Chief Executive Officer









Dr. Hemanth Varghese President & Chief Operating Officer

Our Leadership Team

BAUSCH-Health Sendo BIOVAIL







Domenic Della Penna

Executive Vice President & Chief Financial Officer











Michael Mandarello General Counsel & **Corporate Secretary**









Ross Portaro

Executive Vice President & General Manager, Sales and Marketing









William McGrail

Executive Vice President, R&D. **Technical Operations and** Compliance










Anna Georgiadis

Chief Human Resources Officer







Company Uniquely Positioned in the Aesthetic Industry

| | Face & Skin | Body | Hair Restoration | Hair Removal |
|----------------|-------------|----------|------------------|--------------|
| VENUS | T. | E | E | |
| ♠ C∧NDEL∧™ | | | | |
| CUTERA | | | | |
| SCITON° | | | | |
| (I) INMODE | | | | |
| \$ \$\$ | | | | |
| ::: Allergan | | | | |
| Alma ® | | | | |
| CYTRELLIS | | | | |
| Smart Graft* | | | | |

Offer products in the segment

Offer advanced robotics capability in the space





Only company with advanced robotics & AI/ML capabilities



End-to-end technology and portfolio



Pioneer in aesthetics robotics



Market leader in Hair Restoration / Men's Health




Targeted and diversified global presence



A Company in Evolution







Historical (pre-2023)

- High quality energy-based aesthetic device portfolio
- Uniquely positioned among competitors in hair restoration
- Emphasis on subscription sales (internal financing)
 model
- Global direct presence (peak of 26 direct offices)

Future (post-2023)

- Expected launch of industry first robotics platform in aesthetics
- Rejuvenation of energy-based device portfolio
- Emphasis on **higher quality cash sales model**
- Focused geographic model (<10 direct offices)




Broad Portfolio Offering Across Modalities & Key Segments

| | Product | Segment | | | | Technology | | | | | | |
|---|---------------------------------------------------------------|---------|---------------|-----------------|---------------------|------------|--------------------------|---------------------------------------------------|------------------------------------------------|-------------------------------------|-------------------------|-------------|
| | | Face | Body | Hair Removal | Hair Restoration | Laser | Light (IPL, LED, LHE) | Radio- Frequency (Monopolar, Multipolar) | Electro magnetic Energy (PEMF / HIEF) | Electrical Muscle Stimulation | Robotics or AI / IoT | Mechanical |
| • | Viva MD | | **** | - S * | (E) | | | ✓ | √ | | | |
| • | Versa / Versa Pro | | **** | * | 3 | | ✓ | | | | | |
| • | Velocity | | | ₹* | (a) | √ | | | | | ✓ | |
| • | Legacy | | , 11 , | -8* | (a) | | | √ | √ | | | |
| • | Bliss Max | | → I • | -4* | | √ | | | | \checkmark | √ | |
| • | Neograft | | | -8* | (3) | | | | | | √ | √ |
| • | ARTAS | | | -8* | (3) | | | | | | √] i | |
| • | Epileve | F | | * | 9 | √ | | | | | ✓ | |
| | New Face & Body | | ₩ | -5* | 8 | | | ✓ | ✓ | √ | √ | |
| | AI.ME Platform | | → I • | \$ * | | | | | | | √ \ } | ✓ |
| | = Available in US based on FY2 rces: Company Analysis; Com | | | US website | = Under Devel | opment | = Face & Skin | → = Body | = Hair Res | toration 🁍 : | = Hair Removal | 育 = Robotic |



Market Leading Platforms Across All Key Aesthetic Segments





Venus Viva MD

Fractional RF & MP(2) Technology for Skin Rejuvenation



Unique Technology Offering to Tighten the Skin and Elicit Collagen Formation

SMARTSCAN™

Patented Tip Technology



80 pin tip


(with up to 124 mJ/pin)
for more severe skin concerns-scars, acne scars,
rhytides




160-pin tip

(with up to 62 mJ/pin) for milder skin texture irregularities

Head-to-Head RF Comparison




Venus - Multi Polar RF After 7 minutes



Competitor-Bi polar RF After 15 minutes

Same Power, ½ The Time, 9° Higher!

Evolution & comparison of fractional skin rejuvenation



Results Revealed After 6 Wrinkle Reduction and 3 Skin Resurfacing Treatments



Before





Venus Bliss Max

Complete Body Transformation



The Ultimate 3-in-1 Solution for Body Treatments



Four FlexMAX EMS
applicators
for hands-free muscle
definition and toning

Muscle



Proprietary (MP)2 tech with VariPulse vacuum massage for skin tightening and cellulite reduction

Fat




Four 1,064 nm diode lasers for non-invasive lipolysis with hands-free operation

Skin & Cellulite




Clinical Result of One Diode Laser Treatment

UP TO A 41% REDUCTION IN ADIPOSE LAYER THICKNESS




6 weeks after treatment (0.95 cm) 27% Decrease



12 weeks after treatment (0.80 cm) 41% Decrease

Venus Diode Laser vs Competitors



- Homogenous heating of the hypodermis vs Uneven heating in the issue
- Complete treatment area reached target temp vs Hypodermis does not reach therapeutic temp

Results Revealed After 3 Fat Reduction and 5 Muscle Toning, Skin Treatments







After



Venus Velocity

The Gold Standard in Laser Hair Removal




The Comprehensive Hair Removal Tabletop Solution

Ergonomic Applicators With 3 Changeable Spot Sizes





VENUS



With a wavelength of **800 nm**, Venus Velocity™ provides the optimal balance between high energy absorption of melanin chromophores and deep penetration into the skin, making it **safe and effective for all skin types**, including tanned skin

Advantages Of Diode Over Alex & ND:YAG



Higher Stability

Fewer parts
= less maintenance and inexpensive treatment



Less Cooling Required

Solid state lasers heat up quickly requiring a more aggressive cooling system, which uses a lot of electricity and is prone to failure



Lower Maintenance and Running Costs

Diode lasers are 10x more efficient optically and electrically





After

After 5 Treatments

Before



FY 2023 Product Launch: Versa Pro

Fresh Update of one of Venus's Most Versatile Devices



Strong upgrade opportunity with a potential install base of 2,200+ systems globally, 1,300+ in the US, in addition to new device sales



An improved look & feel, with the addition of the Viva MD applicator and Viva tip consumables to increase recurring revenue base



New system includes:

- New color of the main console
- 10 handpieces, like before, with the addition of Viva MD applicator to replace the Viva applicator
- New 80 pin tips for a deeper ablation and coagulation effect (up to 750nm)
- New branded procedure to leverage combination treatment
- Launch kit including marketing materials & education program






Venus Hair: ARTAS



First and Only Complete Hair Robotics Restoration Platform




ARTAS is the only hair restoration robotic solution available in the market today, leveraging all the distinct advantages of a medical robotic platform: Enhanced HD vision, Customized pre-operative planning and real-time navigation and tracking (supported by AI/ML). With the ARTAS platform, Venus is leading the industry in transitioning from manual FUE to robot-assisted automated HR procedures, enhancing speed and quality of treatment outcomes



Future of Aesthetics Practices

Opportunity to lead introduction of Robotics/AI to enhance treatment delivery





Venus Al.ME

Our Next-Generation Aesthetic Platform





Platform Approach

- Same base platform with automated delivery method and powered by latest AI/ML technology
- ✓ Non-invasive (automated) platform targeting Non-Core segment
- ✓ Non-invasive & Minimally Invasive option targeting Core Physicians

Competitive Advantage

- ✓ Incorporates automation into workflow to reduce human error
- Proven history from Hair Restoration experience
- Flexible in adapting Venus Aesthetic technologies and combination technology offerings
- ✓ State of the art software to deliver high precision outcomes

Technologies

- ✓ Microneedling
- ✓ MP(2)
- ✓ Hair Removal
- ✓ Cellulite
- ✓ Diode Laser

Venus Connect

Leveraging The Power of Our Connected Device Ecosystem





Updated Strategic Plan: Key Pillars

Right sizing the business by rationalizing our international infrastructure, reducing costs and simplifying the organization

02

Changing business model to focus on cash sales and reduce reliance on subscription sales model 03

Focusing on the US
as our primary market
while maintaining an
optimal mix of direct
presence and
distributors in
international

04

Strengthening financial health by simplifying existing capital structure and raising capital to catalyze product and commercial growth drivers 05

Returning to growth through investing in R&D with a focus on robotics with targeted efforts to rejuvenate our energy-based product portfolio and to build a sustainable consumables revenue base to complement device sales. Pursue business development opportunities to accelerate growth and pipeline progress

06

Demonstrating longterm financial sustainability by achieving cash flow break even through execution of product growth plan, managed cost spend, improvement of working capital and focused R&D investments

Completed ✓

Completed √

Completed √

Phase 1

Phase 2 - Current Focus



Strong Results from Phase 1 Turnaround Plan

| Category | Status | FY 2022 | LTM Q3'24 | Commentary | |
|-----------------------------------|-----------|-----------------------------------------|--------------------|------------------------------------------------------------------------|--|
| Dationalizing the Cost Base | // | Cash OPEX | | Reduction of 22% in cash OPEX and 27% in GAAP OPEX | |
| Rationalizing the Cost Base | | \$87M – | → \$68M | period over period | |
| Shifting to Higher Quality | | Cash vs. Sı | ubscription | Successful re-balancing of business model | |
| Revenues | | 58% : 42% | → 69% : 31% | Remaining subscription sales under new credit model | |
| Refocus on the US and | | Direct Offices | | | |
| Optimize International Markets | | 15 - | → 10 | Reduction of 5 offices as of Q4 2024 | |
| Deduction in Oach Daws | | CF From Ops / Unlevered CF ¹ | | 70% and 78% reduction in Cash Flow from Ops and | |
| Reduction in Cash Burn | | (\$27M) / (\$23M) — | → (\$8M) / (\$5M) | Unlevered Cash Flow ¹ , respectively | |

^{1.} Unlevered Cash Flow is defined as Cash Flow from Operations excluding Finance Expenses minus CAPEX



Debt Restructuring Complete to Date

October 2023: Provided Financial Relief & Flexibility for the Company in the Short-Term

Term Loan (CNB)

- On October 5th, 2023, the Company announced that CNB restructured the loan to provide relief and flexibility
- Per the agreement, 100% (\$7.7M) of the 2023 annual payment of principal plus accrued interest is deferred to end of term, and 50% (\$3.9M) of the 2024 annual payment of principal plus accrued interest is deferred to end of term (represents ~\$11.6M in total deferred payment)
- Agreement includes a \$3.0M minimum cash covenant and interest rate reset to 1-month SOFR + 3.25%

April & May 2024:
irst Step in a Multifacet
Plan to Simplify the
Company's Capital
Structure and Provide

Term Loan (Madryn)

- On April 24th, 2024, the Company announced that Madryn purchased the MSLP loan from CNB
- The MSLP Loan balance was \$51.3M as of 12/31/23 and carried an interest rate of 1-month SOFR + 3.25%
- On May 28th, 2024, and September 9th, 2024, Madryn exchanged \$35.0M and \$15.0M, respectively, of the MSLP loan into Series Y Preferred Shares

Convertible Debt (Madryn)

- On October 5th, 2023, the Company announced that Madryn restructured its convertible notes to provide relief and flexibility
- Per the agreement, \$5.0M of the original convertible debt was exchanged for new senior convertible preferred stock, which pays a 12.5% dividend-in-kind on a quarterly basis
- The remaining outstanding balance of the notes bear an interest rate of 3-month adjusted SOFR + 8.5% per annum; interest payments are PIK'd and the notes carry a new conversion price of \$24.00

Bridge Loan (Madryn)

- On April 24th, 2024, the Company announced that Madryn , in conjunction with the MSLP Loan purchase, entered into a Loan and Security Agreement
- The Loan provides up to \$5.0M in debt financing to support the Company's near-term liquidity requirements
- \$2.2M of this facility was drawn down at closing at an interest rate of 12.0% and as of Q3'24, \$4.4M is outstanding



Growth Drivers Based on Key Pillars





Updated R&D roadmap & New Product Innovation strategy (Venus Aesthetics, Venus Hair, AI.ME Robotics, Venus.AI)



Re-structured International Business (Direct, Distributors, Hybrid) and Expanded Market Access (e.g. China, India)



Strong Focus on Cash Generation while Leveraging New Business Solutions (e.g. Venus Prime)



Advance Business Development / M&A Strategy in Aesthetics, Venus Hair and Al.ME Robotics



Longer-Term Aspirations

Growth Aspirations

Operating Cash Flow: ~50% Cash Burn Reduction YoY, Positive in 2026 EBITDA Margin: Positive in 2H 2025, Industry Standard 2026+

'23 & '24

Right size business, refocus business model and rejuvenate R&D

'25

Growth with key pipeline launches **'26+**

Accelerate pipeline / inorganic growth



